Nanomaterials for cancer therapy: current progress and perspectives.

Area of Science:

• Oncology
• Materials Science
• Nanotechnology

Background:

• Current chemotherapy exhibits limitations including lack of specificity, cytotoxicity, and drug resistance.
• Nanomaterials (1-100 nm) possess unique properties beneficial for cancer treatment.
• Existing nano-drug approvals lag behind research advancements.

Purpose of the Study:

• To review novel nanomaterials for cancer therapy.
• To discuss challenges hindering clinical translation of nano-therapeutics.
• To provide suggestions for improved adoption of nanomaterials in oncology.

Main Methods:

• Literature review of nanomaterials in cancer research and clinical use.
• Analysis of nanomaterial applications targeting cancer cells, tumor microenvironment, and immune system.
• Discussion of limitations such as protein corona effects and delivery efficiency.

Main Results:

• Nanomaterials can be engineered to enhance drug specificity, capacity, and bioavailability.
• Targeted delivery systems aim to reduce systemic toxicity and improve therapeutic outcomes.
• Significant research exists, but clinical translation remains a bottleneck.

Conclusions:

• Nanomaterials hold promise for overcoming chemotherapy limitations.
• Addressing challenges in targeted delivery and protein corona is crucial for clinical success.
• Further research and development are essential for efficient adoption of nano-therapeutics in cancer care.